Search clinical trials for: Placebo to MK-0873

Total 1558 results

Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

Respiratory Syncytial Virus | Respiratory Tract Infection

United States, Chile, Colombia, Korea, Republic of, South Africa, Spain
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

Chronic Cough

United States, Argentina, Colombia, Germany, Guatemala, Israel, Korea, Republic of, Peru, Russian Federation, Spain, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)

Chronic Cough

Colombia, Guatemala, Korea, Republic of, Peru, Ukraine, United Kingdom, United States, Canada, Germany, Poland, Russian Federation, Spain
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Obstructive Sleep Apnea (OSA)

United States, Belgium
Merck Sharp & Dohme LLC

Terminated

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Acute Cough

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED)

Hypertension
Merck Sharp & Dohme LLC

Completed

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Type 2 Diabetes (T2D)
Merck Sharp & Dohme LLC

Completed

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

Type 2 Diabetes
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Unknown

Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)

Mild Cognitive Impairment | Alzheimer's Disease
Merck Sharp & Dohme LLC

Not yet recruiting

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Steatohepatitis | Metabolic Dysfunction-associated Steatotic Liver Disease | Metabolic Dysfunction-associated Steatohepatitis
Merck Sharp & Dohme LLC
ALK-Abelló A/S

Completed

MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)

Allergic Rhinitis | Allergic Rhinoconjunctivitis
Merck Sharp & Dohme LLC

Completed

Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)

Migraine
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

Diabetes Mellitus, Type 2
Organon and Co

Completed

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

Hypercholesterolemia
Bill & Melinda Gates Medical Research Institute
Merck Sharp & Dohme LLC

Recruiting

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

Tuberculosis

United States
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)

Chronic Cough

Japan
Merck Sharp & Dohme LLC

Completed

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

Chronic Cough

United States, Argentina, Canada, Czechia, Denmark, France, Hungary, Israel, Japan, Korea, Republic of, Peru, Poland, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)

Immune Thrombocytopenia Purpura
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)

Type 2 Diabetes Mellitus
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Merck Sharp & Dohme LLC
FoxHollow Technologies

Terminated

A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Peripheral Vascular Diseases
ALK-Abelló A/S

Completed

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Allergy | Rhinitis | Conjunctivitis | Rhinoconjunctivitis
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)

Osteoporosis
Famewave Ltd.

Terminated

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Melanoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Non-small Cell Lung Carcinoma (NSCLC)

United States, Israel
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth Disease

United States
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Novo Nordisk A/S

Completed

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Obesity | Overweight

United States, United Kingdom, Canada, Denmark, Finland, Serbia, Poland, Japan, South Africa, Ireland
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Active, not recruiting

A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

Systemic Sclerosis With and Without Interstitial Lung Disease

United States, Canada, Italy, Switzerland
Merck Sharp & Dohme LLC

Completed

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

Kidney Failure, Chronic | End-Stage Renal Disease (ESRD) | End-Stage Kidney Disease (ESKD)

Japan
Merck Sharp & Dohme LLC

Terminated

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

Osteoporosis | Postmenopausal Osteoporosis
Merck Sharp & Dohme LLC
Bayer; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)

Heart Failure | Chronic Heart Failure With Reduced Ejection Fraction
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Psoriasis
Merck Sharp & Dohme LLC

Completed

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Rosacea
Merck Sharp & Dohme LLC

Completed

A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) (MODIFY II)

Clostridium Difficile Infection
Lynn Feun, MD
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) (HYPERION)

Pulmonary Arterial Hypertension

United States, Belgium, France, Germany, Spain, Argentina, Australia, Austria, Colombia, Croatia, Denmark, Greece, Israel, Korea, Republic of, Netherlands, Portugal, Serbia, Taiwan, Brazil, Canada, Czechia, Italy, New Zealand, Sweden, S... and more
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Active, not recruiting

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) (ZENITH)

Pulmonary Arterial Hypertension

France, Germany, United States, Australia, Belgium, Canada, Israel, Italy, Mexico, Netherlands, Spain, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

Chronic Heart Failure With Reduced Ejection Fraction

China, United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Malaysia, Mexico, New Zealand, Peru and more
Afferent Pharmaceuticals, Inc.

Completed

A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)

Cough | Idiopathic Pulmonary Fibrosis
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (PERSEUS1)

Castration-resistant Prostate Cancer

United Kingdom
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Afferent Pharmaceuticals, Inc.

Completed

Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)

Refractory Chronic Cough

United Kingdom
Afferent Pharmaceuticals, Inc.

Completed

A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) (EPICC)

Chronic Cough

3

Subscribe